documents
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
56 rows where docket_id = "FDA-1996-N-0006" and posted_year = 2015 sorted by posted_date descending
This data as json, CSV (advanced)
Suggested facets: subtype, posted_date, posted_month, posted_date (date), comment_start_date (date), comment_end_date (date), last_modified (date)
| id | agency_id | docket_id | title | document_type | subtype | posted_date ▲ | posted_year | posted_month | comment_start_date | comment_end_date | last_modified | fr_doc_num | open_for_comment | withdrawn | object_id |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FDA-1996-N-0006-0176 | FDA | Eligibility Criteria for Considering Additional Conditions in the Over-the-Counter Drug Monograph System FDA-1996-N-0006 | Reference 9 CP1, 81N-0033 re Eligibility Criteria for Considering Additional Conditions in the Over-the-Counter Drug | Supporting & Related Material | Background Material | 2015-07-07T04:00:00Z | 2015 | 7 | 2015-07-07T20:27:50Z | 0 | 0 | 09000064804f9942 | |||
| FDA-1996-N-0006-0177 | FDA | Eligibility Criteria for Considering Additional Conditions in the Over-the-Counter Drug Monograph System FDA-1996-N-0006 | Attachment 5 Conference Report re Comment from Merck KGaA | Supporting & Related Material | Background Material | 2015-07-07T04:00:00Z | 2015 | 7 | 2015-07-07T20:27:50Z | 0 | 0 | 09000064804f9955 | |||
| FDA-1996-N-0006-0178 | FDA | Eligibility Criteria for Considering Additional Conditions in the Over-the-Counter Drug Monograph System FDA-1996-N-0006 | Attachment 4 Review Of Over The Counter Active Ingredients re Comment from Merck KGaA | Supporting & Related Material | Background Material | 2015-07-07T04:00:00Z | 2015 | 7 | 2015-07-07T20:27:50Z | 0 | 0 | 09000064804f9956 | |||
| FDA-1996-N-0006-0180 | FDA | Eligibility Criteria for Considering Additional Conditions in the Over-the-Counter Drug Monograph System FDA-1996-N-0006 | Attachment 3 American Academy Of Dermatology, Sun Protection re Comment from Merck KGaA | Supporting & Related Material | Background Material | 2015-07-07T04:00:00Z | 2015 | 7 | 2015-07-07T20:27:50Z | 0 | 0 | 09000064804f9958 | |||
| FDA-1996-N-0006-0179 | FDA | Eligibility Criteria for Considering Additional Conditions in the Over-the-Counter Drug Monograph System FDA-1996-N-0006 | Attachment 3 Ostroff, The Bottom Line On ASIA re Comment from Merck KGaA | Supporting & Related Material | Background Material | 2015-07-07T04:00:00Z | 2015 | 7 | 2015-07-07T20:27:50Z | 0 | 0 | 09000064804f9957 | |||
| FDA-1996-N-0006-0167 | FDA | Eligibility Criteria for Considering Additional Conditions in the Over-the-Counter Drug Monograph System FDA-1996-N-0006 | Reference 4 CP1, 78N-0038 re Eligibility Criteria for Considering Additional Conditions in the Over-the-Counter Drug | Supporting & Related Material | Background Material | 2015-07-07T04:00:00Z | 2015 | 7 | 2015-07-07T20:27:48Z | 0 | 0 | 09000064804f9939 | |||
| FDA-1996-N-0006-0168 | FDA | Eligibility Criteria for Considering Additional Conditions in the Over-the-Counter Drug Monograph System FDA-1996-N-0006 | Reference 5 CP2, 78N-0038 re Eligibility Criteria for Considering Additional Conditions in the Over-the-Counter Drug | Supporting & Related Material | Background Material | 2015-07-07T04:00:00Z | 2015 | 7 | 2015-07-07T20:27:49Z | 0 | 0 | 09000064804f993a | |||
| FDA-1996-N-0006-0166 | FDA | Eligibility Criteria for Considering Additional Conditions in the Over-the-Counter Drug Monograph System FDA-1996-N-0006 | List of References re Eligibility Criteria for Considering Additional Conditions in the Over-the-Counter Drug Monograph System | Supporting & Related Material | Background Material | 2015-07-07T04:00:00Z | 2015 | 7 | 2015-07-07T20:27:48Z | 0 | 0 | 09000064804f9938 | |||
| FDA-1996-N-0006-0170 | FDA | Eligibility Criteria for Considering Additional Conditions in the Over-the-Counter Drug Monograph System FDA-1996-N-0006 | Reference 13 CP1, 95P-0145 re Eligibility Criteria for Considering Additional Conditions in the Over-the-Counter Drug | Supporting & Related Material | Background Material | 2015-07-07T04:00:00Z | 2015 | 7 | 2015-07-07T20:27:49Z | 0 | 0 | 09000064804f993c | |||
| FDA-1996-N-0006-0175 | FDA | Eligibility Criteria for Considering Additional Conditions in the Over-the-Counter Drug Monograph System FDA-1996-N-0006 | Reference 8 C105, 78N-0038 re Eligibility Criteria for Considering Additional Conditions in the Over-the-Counter Drug | Supporting & Related Material | Background Material | 2015-07-07T04:00:00Z | 2015 | 7 | 2015-07-07T20:27:49Z | 0 | 0 | 09000064804f9941 | |||
| FDA-1996-N-0006-0165 | FDA | Eligibility Criteria for Considering Additional Conditions in the Over-the-Counter Drug Monograph System FDA-1996-N-0006 | Reference 1 PDN2, 77N-0094 re Eligibility Criteria for Considering Additional Conditions in the Over-the-Counter Drug Monograph System | Supporting & Related Material | Background Material | 2015-07-07T04:00:00Z | 2015 | 7 | 2015-07-07T20:27:48Z | 0 | 0 | 09000064804f9937 | |||
| FDA-1996-N-0006-0163 | FDA | Eligibility Criteria for Considering Additional Conditions in the Over-the-Counter Drug Monograph System FDA-1996-N-0006 | Reference 3 Letter from Thomas Scarlett re Eligibility Criteria for Considering Additional Conditions in the Over-the-Counter Drug Monograph System | Supporting & Related Material | Background Material | 2015-07-07T04:00:00Z | 2015 | 7 | 2015-07-07T20:27:48Z | 0 | 0 | 09000064804f9935 | |||
| FDA-1996-N-0006-0173 | FDA | Eligibility Criteria for Considering Additional Conditions in the Over-the-Counter Drug Monograph System FDA-1996-N-0006 | Reference 10 CP1, 92P-0309 re Eligibility Criteria for Considering Additional Conditions in the Over-the-Counter Drug | Supporting & Related Material | Background Material | 2015-07-07T04:00:00Z | 2015 | 7 | 2015-07-07T20:27:49Z | 0 | 0 | 09000064804f993f | |||
| FDA-1996-N-0006-0161 | FDA | Eligibility Criteria for Considering Additional Conditions in the Over-the-Counter Drug Monograph System FDA-1996-N-0006 | Request for Extension from Merck KGaA & U.S. EM Industries, Inc. | Other | Request for Extension | 2015-07-07T04:00:00Z | 2015 | 7 | 2015-07-07T04:00:00Z | 2015-07-07T20:25:46Z | 0 | 0 | 09000064804f9965 | ||
| FDA-1996-N-0006-0174 | FDA | Eligibility Criteria for Considering Additional Conditions in the Over-the-Counter Drug Monograph System FDA-1996-N-0006 | Reference 7 CP4, 78N-0308 re Eligibility Criteria for Considering Additional Conditions in the Over-the-Counter Drug | Supporting & Related Material | Background Material | 2015-07-07T04:00:00Z | 2015 | 7 | 2015-07-07T20:27:49Z | 0 | 0 | 09000064804f9940 | |||
| FDA-1996-N-0006-0172 | FDA | Eligibility Criteria for Considering Additional Conditions in the Over-the-Counter Drug Monograph System FDA-1996-N-0006 | Reference 11 CP1, 94P-0215 re Eligibility Criteria for Considering Additional Conditions in the Over-the-Counter Drug | Supporting & Related Material | Background Material | 2015-07-07T04:00:00Z | 2015 | 7 | 2015-07-07T20:27:49Z | 0 | 0 | 09000064804f993e | |||
| FDA-1996-N-0006-0171 | FDA | Eligibility Criteria for Considering Additional Conditions in the Over-the-Counter Drug Monograph System FDA-1996-N-0006 | Reference 12 CP2, 94P-0215 re Eligibility Criteria for Considering Additional Conditions in the Over-the-Counter Drug | Supporting & Related Material | Background Material | 2015-07-07T04:00:00Z | 2015 | 7 | 2015-07-07T20:27:49Z | 0 | 0 | 09000064804f993d | |||
| FDA-1996-N-0006-0182 | FDA | Eligibility Criteria for Considering Additional Conditions in the Over-the-Counter Drug Monograph System FDA-1996-N-0006 | OMB Revisions of the final Rule re Additional Criteria and Procedures for Classifying OTC Drugs as Generally Recognized as Safe and Effective and not Misbranded | Supporting & Related Material | Reference (internal unless indicated) | 2015-07-07T04:00:00Z | 2015 | 7 | 2015-07-07T20:27:50Z | 0 | 0 | 09000064804f9979 | |||
| FDA-1996-N-0006-0164 | FDA | Eligibility Criteria for Considering Additional Conditions in the Over-the-Counter Drug Monograph System FDA-1996-N-0006 | Reference 2 Let95, 78N-0038 re Eligibility Criteria for Considering Additional Conditions in the Over-the-Counter Drug Monograph System | Supporting & Related Material | Background Material | 2015-07-07T04:00:00Z | 2015 | 7 | 2015-07-07T20:27:48Z | 0 | 0 | 09000064804f9936 | |||
| FDA-1996-N-0006-0181 | FDA | Eligibility Criteria for Considering Additional Conditions in the Over-the-Counter Drug Monograph System FDA-1996-N-0006 | Attachment 1 Letter of Authorization re Comment from Merck KGaA | Supporting & Related Material | Background Material | 2015-07-07T04:00:00Z | 2015 | 7 | 2015-07-07T20:27:50Z | 0 | 0 | 09000064804f9959 | |||
| FDA-1996-N-0006-0169 | FDA | Eligibility Criteria for Considering Additional Conditions in the Over-the-Counter Drug Monograph System FDA-1996-N-0006 | Reference 6 CP3, 78N-0038 re Eligibility Criteria for Considering Additional Conditions in the Over-the-Counter Drug | Supporting & Related Material | Background Material | 2015-07-07T04:00:00Z | 2015 | 7 | 2015-07-07T20:27:49Z | 0 | 0 | 09000064804f993b | |||
| FDA-1996-N-0006-0131 | FDA | Eligibility Criteria for Considering Additional Conditions in the Over-the-Counter Drug Monograph System FDA-1996-N-0006 | Letter from Personal Care Products Council and Consumer Healthcare Products Association to FDA CDER | Other | Letter(s) | 2015-03-20T04:00:00Z | 2015 | 3 | 2015-03-20T04:00:00Z | 2015-05-05T20:05:57Z | 0 | 0 | 0900006481a548dc | ||
| FDA-1996-N-0006-0119 | FDA | Eligibility Criteria for Considering Additional Conditions in the Over-the-Counter Drug Monograph System FDA-1996-N-0006 | Reference 19 - Faas et al, Female Sexual Behavior, Estrous Cycle and Gene Expression in Sexually Dimorphic Brain Regions After Pre- and Postnatal Exposure to Endocrine Active UV Filters re Over-the-Counter Sunscreen Drug Products - Regulatory Status of Enzacamene | Supporting & Related Material | Background Material | 2015-02-25T05:00:00Z | 2015 | 2 | 2015-06-22T15:14:46Z | 0 | 0 | 0900006481a11365 | |||
| FDA-1996-N-0006-0124 | FDA | Eligibility Criteria for Considering Additional Conditions in the Over-the-Counter Drug Monograph System FDA-1996-N-0006 | Reference 24 - Schlumpf et al, Estrogenic Activity and Estrogen Receptor Beta Binding of the UV Filter 3-Benzylidene Camphor. Comparison With 4-Methylbenzylidene Camphor re Over-the-Counter Sunscreen Drug Products - Regulatory Status of Enzacamene | Supporting & Related Material | Background Material | 2015-02-25T05:00:00Z | 2015 | 2 | 2015-06-22T15:26:23Z | 0 | 0 | 0900006481a1137b | |||
| FDA-1996-N-0006-0101 | FDA | Eligibility Criteria for Considering Additional Conditions in the Over-the-Counter Drug Monograph System FDA-1996-N-0006 | Reference 1 - FDA, Guidance for industry, Photosafety Testing, May 2003 re Over-the-Counter Sunscreen Drug Products - Regulatory Status of Enzacamene | Supporting & Related Material | Background Material | 2015-02-25T05:00:00Z | 2015 | 2 | 2015-06-22T14:09:48Z | 0 | 0 | 0900006481a11045 | |||
| FDA-1996-N-0006-0130 | FDA | Eligibility Criteria for Considering Additional Conditions in the Over-the-Counter Drug Monograph System FDA-1996-N-0006 | Reference 30 - International Conference on Harmonization (ICH) Toxicokinetics: The Assessment of Systemic Exposure in Toxicity Studies S3A, March 1995 re Over-the-Counter Sunscreen Drug Products - Regulatory Status of Enzacamene | Supporting & Related Material | Background Material | 2015-02-25T05:00:00Z | 2015 | 2 | 2015-06-22T15:58:34Z | 0 | 0 | 0900006481a1139e | |||
| FDA-1996-N-0006-0104 | FDA | Eligibility Criteria for Considering Additional Conditions in the Over-the-Counter Drug Monograph System FDA-1996-N-0006 | Reference 4 - Schauer, et al, Kinetics of 3-(methylbenzlidene) Camphor in Rats and Humans After Dermal Application re Over-the-Counter Sunscreen Drug Products - Regulatory Status of Enzacamene | Supporting & Related Material | Background Material | 2015-02-25T05:00:00Z | 2015 | 2 | 2015-06-22T14:26:52Z | 0 | 0 | 0900006481a1104b | |||
| FDA-1996-N-0006-0120 | FDA | Eligibility Criteria for Considering Additional Conditions in the Over-the-Counter Drug Monograph System FDA-1996-N-0006 | Reference 20 - Hofkamp et al, Region-Specific Growth Effects in the Developing Rat Prostate Following Fetal Exposure to Estrogenic Ultraviolet Filters re Over-the-Counter Sunscreen Drug Products - Regulatory Status of Enzacamene | Supporting & Related Material | Background Material | 2015-02-25T05:00:00Z | 2015 | 2 | 2015-06-22T15:16:09Z | 0 | 0 | 0900006481a11373 | |||
| FDA-1996-N-0006-0127 | FDA | Eligibility Criteria for Considering Additional Conditions in the Over-the-Counter Drug Monograph System FDA-1996-N-0006 | Reference 27 - Guidance for Industry, S1B Testing for Carcinogenicity of Pharmaceuticals, July 1997 re Over-the-Counter Sunscreen Drug Products - Regulatory Status of Enzacamene | Supporting & Related Material | Background Material | 2015-02-25T05:00:00Z | 2015 | 2 | 2015-06-22T15:36:17Z | 0 | 0 | 0900006481a1138b | |||
| FDA-1996-N-0006-0100 | FDA | Eligibility Criteria for Considering Additional Conditions in the Over-the-Counter Drug Monograph System FDA-1996-N-0006 | Over-the-Counter Sunscreen Drug Products—Regulatory Status of Enzacamene | Proposed Rule | Notice of Proposed Rulemaking (NPRM) | 2015-02-25T05:00:00Z | 2015 | 2 | 2015-02-25T05:00:00Z | 2015-04-14T03:59:59Z | 2015-02-25T17:40:37Z | 2015-03884 | 0 | 0 | 0900006481a16b78 |
| FDA-1996-N-0006-0128 | FDA | Eligibility Criteria for Considering Additional Conditions in the Over-the-Counter Drug Monograph System FDA-1996-N-0006 | Reference 28 - International Conference on Harmonization (ICH) Guidance for Industry - S1C(R2) Dose Selection for Carcinogenicity Studies of Pharmaceuticals SIC(R2) (Revision 1), September 2008 re Over-the-Counter Sunscreen Drug Products - Regulatory Status of Enzacamene | Supporting & Related Material | Background Material | 2015-02-25T05:00:00Z | 2015 | 2 | 2015-06-22T15:38:44Z | 0 | 0 | 0900006481a1138d | |||
| FDA-1996-N-0006-0113 | FDA | Eligibility Criteria for Considering Additional Conditions in the Over-the-Counter Drug Monograph System FDA-1996-N-0006 | Reference 13 - Schreurs et al, Estrogenic Activity of UV Filters Determined by an In Vitro Reporter Gene Assay and an In Vivo Transgenic Zebrafish Assay re Over-the-Counter Sunscreen Drug Products - Regulatory Status of Enzacamene | Supporting & Related Material | Background Material | 2015-02-25T05:00:00Z | 2015 | 2 | 2015-06-22T14:51:58Z | 0 | 0 | 0900006481a11349 | |||
| FDA-1996-N-0006-0123 | FDA | Eligibility Criteria for Considering Additional Conditions in the Over-the-Counter Drug Monograph System FDA-1996-N-0006 | Reference 23 - Schlumpf et al, In Vitro and In Vivo Estrogenicity of UV Screens re Over-the-Counter Sunscreen Drug Products - Regulatory Status of Enzacamene | Supporting & Related Material | Background Material | 2015-02-25T05:00:00Z | 2015 | 2 | 2015-06-22T15:22:10Z | 0 | 0 | 0900006481a11379 | |||
| FDA-1996-N-0006-0129 | FDA | Eligibility Criteria for Considering Additional Conditions in the Over-the-Counter Drug Monograph System FDA-1996-N-0006 | Reference 29 - International Conference on Harmonization (ICH) Harmonized Tripartite Guideline for Industry, Detection of Toxicity to Reproduction for Medicinal Products & Toxicity to Male Fertility S5(R2), 2005 re Over-the-Counter Sunscreen Drug Products - Regulatory Status of Enzacamene | Supporting & Related Material | Background Material | 2015-02-25T05:00:00Z | 2015 | 2 | 2015-06-22T15:51:28Z | 0 | 0 | 0900006481a1138f | |||
| FDA-1996-N-0006-0102 | FDA | Eligibility Criteria for Considering Additional Conditions in the Over-the-Counter Drug Monograph System FDA-1996-N-0006 | Reference 2 - FDA, Guidance for Industry, Guideline for the Format and Content of the Human Pharmacokinetics and Bioavailability Section of an Application, February 1987 re Over-the-Counter Sunscreen Drug Products - Regulatory Status of Enzacamene | Supporting & Related Material | Background Material | 2015-02-25T05:00:00Z | 2015 | 2 | 2015-06-22T14:20:03Z | 0 | 0 | 0900006481a11047 | |||
| FDA-1996-N-0006-0103 | FDA | Eligibility Criteria for Considering Additional Conditions in the Over-the-Counter Drug Monograph System FDA-1996-N-0006 | Reference 3 - Janjua, et al Systemic Absorption of the Sunscreens Benzophenone-3, Octyl-Methoxycinnamate, and 3-(4-Methyl-Benzylidene) Camphor After Whole Body Topical Application and Reproductive Hormone Levels in Humans re Over-the-Counter Sunscreen Drug Products - Regulatory Status of Enzacamene | Supporting & Related Material | Background Material | 2015-02-25T05:00:00Z | 2015 | 2 | 2015-06-22T14:22:03Z | 0 | 0 | 0900006481a11049 | |||
| FDA-1996-N-0006-0107 | FDA | Eligibility Criteria for Considering Additional Conditions in the Over-the-Counter Drug Monograph System FDA-1996-N-0006 | Reference 7- Jimenez-Diaz et al, Simultaneous Determination of the UV-Filters Benzyl Salicylate, Phenyl Salicylate, Octyl Salicylate, Homosalate, 3-(4-Methylbenzylidene) Camphor and 3-Benzylidene Camphor in Human Placental Tissue by LC-MS/MS. Assessment of Their In Vitro Endocrine Activity re Over-the-Counter Sunscreen Drug Products - Regulatory Status of Enzacamene | Supporting & Related Material | Background Material | 2015-02-25T05:00:00Z | 2015 | 2 | 2015-06-22T14:41:11Z | 0 | 0 | 0900006481a11332 | |||
| FDA-1996-N-0006-0109 | FDA | Eligibility Criteria for Considering Additional Conditions in the Over-the-Counter Drug Monograph System FDA-1996-N-0006 | Reference 9 - Ma et al, UV Filters With Antagonistic Action at Androgen Receptors in the MDA-kb2 Cell Transcriptional-Activation Assay re Over-the-Counter Sunscreen Drug Products - Regulatory Status of Enzacamene | Supporting & Related Material | Background Material | 2015-02-25T05:00:00Z | 2015 | 2 | 2015-06-22T14:46:34Z | 0 | 0 | 0900006481a11337 | |||
| FDA-1996-N-0006-0112 | FDA | Eligibility Criteria for Considering Additional Conditions in the Over-the-Counter Drug Monograph System FDA-1996-N-0006 | Reference 12 - Schmutzler et al, Endocrine Disruptors and the Thyroid Gland-A Combined In Vitro and In Vivo Analysis of Potential New Biomarkers re Over-the-Counter Sunscreen Drug Products - Regulatory Status of Enzacamene | Supporting & Related Material | Background Material | 2015-02-25T05:00:00Z | 2015 | 2 | 2015-06-22T14:50:16Z | 0 | 0 | 0900006481a11347 | |||
| FDA-1996-N-0006-0115 | FDA | Eligibility Criteria for Considering Additional Conditions in the Over-the-Counter Drug Monograph System FDA-1996-N-0006 | Reference 15 - Soeborg et al, Risk Assessment of Topically Applied Products re Over-the-Counter Sunscreen Drug Products - Regulatory Status of Enzacamene | Supporting & Related Material | Background Material | 2015-02-25T05:00:00Z | 2015 | 2 | 2015-06-22T14:59:57Z | 0 | 0 | 0900006481a1135d | |||
| FDA-1996-N-0006-0126 | FDA | Eligibility Criteria for Considering Additional Conditions in the Over-the-Counter Drug Monograph System FDA-1996-N-0006 | Reference 26 - International Conference on Harmonization (ICH), Guidance for Industry, The Need for Long Term Rodent Carcinogenicity Studies of Pharmaceuticals S1A, March 1996 re Over-the-Counter Sunscreen Drug Products - Regulatory Status of Enzacamene | Supporting & Related Material | Background Material | 2015-02-25T05:00:00Z | 2015 | 2 | 2015-06-22T15:31:30Z | 0 | 0 | 0900006481a11389 | |||
| FDA-1996-N-0006-0114 | FDA | Eligibility Criteria for Considering Additional Conditions in the Over-the-Counter Drug Monograph System FDA-1996-N-0006 | Reference 14 - Seidlova Wuttke et al, Comparison of Effects of Estradiol With Those of Octylmethoxycinnamate and 4-Methylbenzylidene Camphor on Fat Tissue, Lipids and Pituitary Hormones re Over-the-Counter Sunscreen Drug Products - Regulatory Status of Enzacamene | Supporting & Related Material | Background Material | 2015-02-25T05:00:00Z | 2015 | 2 | 2015-06-22T14:56:40Z | 0 | 0 | 0900006481a1134b | |||
| FDA-1996-N-0006-0122 | FDA | Eligibility Criteria for Considering Additional Conditions in the Over-the-Counter Drug Monograph System FDA-1996-N-0006 | Reference 22 - Maerkel et al, Sex- and Region-Specific Alterations of Progesterone Receptor mRNA Levels and Estrogen Sensitivity in Rat Brain Following Developmental Exposure to the Estrogenic UV Filter 4-Methylbenzylidene Camphor re Over-the-Counter Sunscreen Drug Products - Regulatory Status of Enzacamene | Supporting & Related Material | Background Material | 2015-02-25T05:00:00Z | 2015 | 2 | 2015-06-22T15:21:22Z | 0 | 0 | 0900006481a11377 | |||
| FDA-1996-N-0006-0117 | FDA | Eligibility Criteria for Considering Additional Conditions in the Over-the-Counter Drug Monograph System FDA-1996-N-0006 | Reference 17 - Durrer et al, Estrogen Sensitivity of Target Genes and Expression of Nuclear Receptor Co-Regulators in Rat Prostate After Pre- and Postnatal Exposure to the Ultraviolet Filter 4-Methylbenzylidene Camphor re Over-the-Counter Sunscreen Drug Products - Regulatory Status of Enzacamene | Supporting & Related Material | Background Material | 2015-02-25T05:00:00Z | 2015 | 2 | 2015-06-22T15:09:41Z | 0 | 0 | 0900006481a11361 | |||
| FDA-1996-N-0006-0121 | FDA | Eligibility Criteria for Considering Additional Conditions in the Over-the-Counter Drug Monograph System FDA-1996-N-0006 | Reference 21 - Maerkel et al, Sexually Dimorphic Gene Regulation in Brain as a Target for Endocrine Disrupters: Developmental Exposure of Rats to 4-Methylbenzylidene Camphor re Over-the-Counter Sunscreen Drug Products - Regulatory Status of Enzacamene | Supporting & Related Material | Background Material | 2015-02-25T05:00:00Z | 2015 | 2 | 2015-06-22T15:19:32Z | 0 | 0 | 0900006481a11375 | |||
| FDA-1996-N-0006-0105 | FDA | Eligibility Criteria for Considering Additional Conditions in the Over-the-Counter Drug Monograph System FDA-1996-N-0006 | Reference 5 - Janjua et al, Sunscreens in Human Plasma and Urine After Repeated Whole-Body Topical Application re Over-the-Counter Sunscreen Drug Products - Regulatory Status of Enzacamene | Supporting & Related Material | Background Material | 2015-02-25T05:00:00Z | 2015 | 2 | 2015-06-22T14:30:38Z | 0 | 0 | 0900006481a1104d | |||
| FDA-1996-N-0006-0106 | FDA | Eligibility Criteria for Considering Additional Conditions in the Over-the-Counter Drug Monograph System FDA-1996-N-0006 | Reference 6 - Scientific Committee on Consumer Products (SCCP)/1184/08-SCCNFP Opinion on 4-Methylbenzylidene Camphor (4-MBC) Colipa n° S60 Adopted During the 16th Plenary Meeting of June 24, 2008 re Over-the-Counter Sunscreen Drug Products - Regulatory Status of Enzacamene | Supporting & Related Material | Background Material | 2015-02-25T05:00:00Z | 2015 | 2 | 2015-06-22T14:37:31Z | 0 | 0 | 0900006481a11330 | |||
| FDA-1996-N-0006-0110 | FDA | Eligibility Criteria for Considering Additional Conditions in the Over-the-Counter Drug Monograph System FDA-1996-N-0006 | Reference 10 - Mueller et al, Activation of Estrogen Receptor Alpha and ERbeta by 4-Methylbenzylidene-Camphor in Human and Rat Cells: Comparison With Phyto- and Xenoestrogens re Over-the-Counter Sunscreen Drug Products - Regulatory Status of Enzacamene | Supporting & Related Material | Background Material | 2015-02-25T05:00:00Z | 2015 | 2 | 2015-06-22T14:47:50Z | 0 | 0 | 0900006481a11343 | |||
| FDA-1996-N-0006-0125 | FDA | Eligibility Criteria for Considering Additional Conditions in the Over-the-Counter Drug Monograph System FDA-1996-N-0006 | Reference 25 - Schlumpf et al, Endocrine Activity and Developmental Toxicity of Cosmetic UV Filters-An Update re Over-the-Counter Sunscreen Drug Products - Regulatory Status of Enzacamene | Supporting & Related Material | Background Material | 2015-02-25T05:00:00Z | 2015 | 2 | 2015-06-22T15:27:47Z | 0 | 0 | 0900006481a11387 | |||
| FDA-1996-N-0006-0108 | FDA | Eligibility Criteria for Considering Additional Conditions in the Over-the-Counter Drug Monograph System FDA-1996-N-0006 | Reference 8 - Gomez et al, Estrogenic Activity of Cosmetic Components in Reporter Cell Lines: Parabens, UV Screens and Musks re Over-the-Counter Sunscreen Drug Products - Regulatory Status of Enzacamene | Supporting & Related Material | Background Material | 2015-02-25T05:00:00Z | 2015 | 2 | 2015-06-22T14:46:11Z | 0 | 0 | 0900006481a11335 | |||
| FDA-1996-N-0006-0116 | FDA | Eligibility Criteria for Considering Additional Conditions in the Over-the-Counter Drug Monograph System FDA-1996-N-0006 | Reference 16 -Tinwell et al, Confirmation of Uterotrophic Activity of 3-(4-Methylbenzylidine) Camphor in the Immature Rat re Over-the-Counter Sunscreen Drug Products - Regulatory Status of Enzacamene | Supporting & Related Material | Background Material | 2015-02-25T05:00:00Z | 2015 | 2 | 2015-06-22T15:03:10Z | 0 | 0 | 0900006481a1135f | |||
| FDA-1996-N-0006-0118 | FDA | Eligibility Criteria for Considering Additional Conditions in the Over-the-Counter Drug Monograph System FDA-1996-N-0006 | Reference 18 - Durrer et al, Estrogen Target Gene Regulation and Coactivator Expression in Rat Uterus After Developmental Exposure to the Ultraviolet Filter 4-Methylbenzylidene Camphor re Over-the-Counter Sunscreen Drug Products - Regulatory Status of Enzacamene | Supporting & Related Material | Background Material | 2015-02-25T05:00:00Z | 2015 | 2 | 2015-06-22T15:10:46Z | 0 | 0 | 0900006481a11363 | |||
| FDA-1996-N-0006-0111 | FDA | Eligibility Criteria for Considering Additional Conditions in the Over-the-Counter Drug Monograph System FDA-1996-N-0006 | Reference 11 - Schlumpf et al, Estrogenic Activity and Estrogen Receptor Beta Binding of the UV Filter 3-Benzylidene Camphor. Comparison With 4-Methylbenzylidene Camphor re Over-the-Counter Sunscreen Drug Products - Regulatory Status of Enzacamene | Supporting & Related Material | Background Material | 2015-02-25T05:00:00Z | 2015 | 2 | 2015-06-22T14:48:48Z | 0 | 0 | 0900006481a11345 | |||
| FDA-1996-N-0006-0098 | FDA | Eligibility Criteria for Considering Additional Conditions in the Over-the-Counter Drug Monograph System FDA-1996-N-0006 | Summary of Meeting Announcement from FDA CDER re FDA Implementation of the Sunscreen Innovation Act SIA February 4 2015, FDA-1996-N-0006-0097 | Supporting & Related Material | Meeting Summary | 2015-02-23T05:00:00Z | 2015 | 2 | 2015-05-13T13:55:57Z | 0 | 0 | 0900006481a103e1 | |||
| FDA-1996-N-0006-0099 | FDA | Eligibility Criteria for Considering Additional Conditions in the Over-the-Counter Drug Monograph System FDA-1996-N-0006 | Slide Presentatition from the Sunscreen Innovation Act Stakeholder Meeting re FDA Implementation of the Sunscreen Innovation Act SIA February 4 2015, FDA-1996-N-0006-0097 | Supporting & Related Material | Meeting Materials | 2015-02-23T05:00:00Z | 2015 | 2 | 2015-02-23T22:19:50Z | 0 | 0 | 0900006481a1078d | |||
| FDA-1996-N-0006-0097 | FDA | Eligibility Criteria for Considering Additional Conditions in the Over-the-Counter Drug Monograph System FDA-1996-N-0006 | Meeting Announcement from FDA CDER re FDA Implementation of the Sunscreen Innovation Act (SIA), February 4 2015 | Other | Memorandum | 2015-01-26T05:00:00Z | 2015 | 1 | 2015-01-26T05:00:00Z | 2015-05-05T20:00:27Z | 0 | 0 | 09000064819e06e2 |
Advanced export
JSON shape: default, array, newline-delimited, object
CREATE TABLE documents (
id TEXT PRIMARY KEY,
agency_id TEXT,
docket_id TEXT REFERENCES dockets(id),
title TEXT,
document_type TEXT,
subtype TEXT,
posted_date TEXT,
posted_year INTEGER,
posted_month INTEGER,
comment_start_date TEXT,
comment_end_date TEXT,
last_modified TEXT,
fr_doc_num TEXT,
open_for_comment INTEGER,
withdrawn INTEGER,
object_id TEXT
);
CREATE INDEX idx_docs_agency ON documents(agency_id);
CREATE INDEX idx_docs_docket ON documents(docket_id);
CREATE INDEX idx_docs_date ON documents(posted_date);
CREATE INDEX idx_docs_year ON documents(posted_year);
CREATE INDEX idx_docs_type ON documents(document_type);
CREATE INDEX idx_docs_frnum ON documents(fr_doc_num);